108 results about "Cord blood stem cell" patented technology

The invention provides a hematologic tumor cord blood transplantation treatment prognosis risk assessment method and system based on multi-modal data fusion, a medium and electronic equipment, and relates to the technical field of medical artificial intelligence and clinical decision support systems. The method comprises the following steps: acquiring multi-modal data including unit characteristic data of cord blood of a patient, biomarker data and the like; screening out a simplified feature set from the preprocessed multi-modal data; fusing the simplified features based on three complementary strategies of feature level direct cascade, knowledge graph semantic association and multi-model decision integration; and a prediction model is constructed, and a standardized risk assessment report is generated based on the optimized hierarchical risk levels and is used for assisting clinical decision support. According to the method, accurate layering of the prognosis risk of the hematologic tumor umbilical cord blood transplantation patient is achieved, high-accuracy risk prediction is provided, good interpretability and personalized decision support capacity are achieved, and a scientific basis is provided for clinical practice.

Embodiments of the invention include compositions and methods related to engineered human mucosal-associated invariant T (eMAIT) cells for off-the-shelf use for clinical therapy for cancer, infectious, and autoimmune diseases. In some embodiments, the eMAIT cells are produced from healthy human donor peripheral blood, cord blood, or G-CSF mobilized peripheral blood. In particular embodiments, the eMAIT cells are produced from a pluripotent stem cell line and therefore can be of unlimited supply. In some embodiments, the eMAIT cells are engineered to express chimeric antigen receptors (CARs), or / and immune regulatory molecules, or / and allorejection resistance molecules. Embodiments of the invention also include compositions of matter comprising polynucleotides encoding mucosal-associated invariant T cell receptor alpha chain polypeptides and / or mucosal-associated invariant T cell receptor beta chain polypeptides.

The invention discloses a cord blood-derived hematopoietic stem cell as well as an amplification method and application thereof. The method comprises the step of culturing umbilical cord blood mononuclear cells by using a culture medium containing thymus active polypeptide, stem cell growth factors and heat shock protein. According to the method for amplifying the umbilical cord blood-derived hematopoietic stem cells, the proliferation efficiency of umbilical cord blood mononuclear cells can be remarkably improved, and the amplification capacity of umbilical cord blood immune cells (NK cells) is improved by more than 5 times compared with that of a traditional method.

The invention relates to a method of producing a clonal mesenchymal stem cell line capable of producing exosomes (MSC-derived extracellular vesicles) comprising the steps of, providing human induced pluripotent stem cells (hiPSCs), generating therefrom an immortalized clonal cell line of mesenchymal stem cells (IMSC), optionally characterizing the potential of the IMSCs to produce exosomes. The invention also relates to a stem cell line produced according to the invention. The invention relates to the cell line according to the invention, for use as a medicament. The invention relates to the cell line according to the invention for use in treating a disease that is amenable to treatment with stem cell therapy. The invention also relates to the use of a stem cell line according to the invention for producing EVs.

A method of generating a hematopoietic cell, including providing a source cell and treating the source cell with a metabolic regulator that directs the source cell to preferentially use glycolysis or oxidative phosphorylation and / or cholesterol biosynthesis, wherein the source cell is differentiated into a GPA+ erythroid cell or a CD45+ non-erythroid cell. In some examples, the source cell is selected from the group consisting of a hemogenic endothelial (HE) cell, a iPS cell such as a differentiating iPS cell, a cell directly reprogrammed to a known pre-cursor of a hematopoietic cell, a cell directly reprogrammed to a hematopoietic cell or precursor of a hematopoietic cell, a reprogrammed cell that is subsequently further reprogrammed to a hematopoietic cell or precursor of a hematopoietic cell, an adult hematopoietic cell derived from bone marrow or mobilized peripheral blood and a neonatal hematopoietic cell derived from cord blood or prenatal tissue (e.g. placenta). Some examples involve metabolically regulating a lipid biosynthesis pathway with an inhibitor of the lipid biosynthesis pathway or metabolically regulating a histone acetylation pathway with an inhibitor of the histone acetylation pathway.

The present disclosure provides a method for in vitro expansion of cryopreserved cord blood-derived regulatory T cells (Tregs) with a high recovery rate, including the following steps: recovering the cryopreserved cord blood-derived Tregs after first expansion, and resuspending the cells with a serum-free medium; and adding a resulting suspension to an expansion culture medium, and conducting a second expansion culture, where a primary culture is conducted for 1 d to 2 d, then a subculture is conducted once every 1 d to 3 d, and a total culture time is 13 d or more. In the expansion culture medium, interleukin-2 (IL-2) is further added. The method of the present disclosure can achieve the second recovery and expansion of cryopreserved Tregs produced after the first expansion. Tregs produced after the second recovery and expansion can have a viability of 90% or more, and can be further expanded (such as third expansion and fourth expansion). The expanded cells can also be used for clinical treatment. Therefore, the method of the present disclosure greatly shortens the time for clinical patients to wait for Tregs, and can meet the clinical on-demand access requirement.

Described herein are methods for cell wash, isolation and cryopreservation of frozen umbilical cord blood which can allow for reprogramming iPSCs from cord blood. Also described herein are methods of cord blood unit processing and cell enrichment. The methods are in accordance with current good manufacturing practices.

The utility model relates to the technical field of medical equipment, in particular to a cord blood stem cell preservation bag which comprises a preservation bag body, a connector is arranged at the top of the preservation bag body, a protection assembly is arranged outside the preservation bag body and comprises a protection sleeve, the protection sleeve is connected outside the preservation bag body in a sleeved mode, and the protection sleeve is connected with the connector. A first hole is formed in the upper surface of the protective sleeve, a protective ring is connected into the first hole in a sleeved mode, a sealing ring is fixedly connected to the bottom of the protective ring, a buffer block is fixedly connected to the bottom of the protective sleeve, and a sealing edge is fixedly connected to the outer portion of the protective sleeve. According to the umbilical cord blood stem cell preservation bag, by installing the protection assembly, when the preservation bag is used for storing umbilical cord blood, the bag body can be protected through the protection sleeve, the bag body is prevented from being damaged in the use process, meanwhile, the protection ring is used for fixing and protecting the blood sampling connector, and the situation that the blood sampling connector is exposed, and blood in the bag body is affected is avoided; and therefore, the protection bag is more stable in use.

To provide a natural killer T cell (NKT cell) therapy that does not need activation with α-galactosyl ceramide (Gal-Cer).SOLUTION: Provided herein are CIK NKT cells that can be activated in the absence of Gal-Cer. In some embodiments, more than 50% of the cells in the CIK NKT cell population express CD56 and CD3, and less than 10% of the cells in the population express Va24. Also provided are compositions and kits comprising a plurality of CIK NKT cells from the population. Methods of producing the CIK NKT cells and methods of using the cells to treat cancer are also provided.SELECTED DRAWING: Figure 2

The utility model relates to the technical field of medical research, in particular to a perfusion device for cord blood mesenchymal stem cell culture, which comprises a base, the upper end of the base is fixedly connected with a plurality of supports, the upper ends of the supports are fixedly connected with a support plate, the upper end of the support plate is fixedly connected with a nutrition box, and the outer side of the lower end of the nutrition box is fixedly communicated with a parallel communication device; the perfusion device for umbilical cord blood mesenchymal stem cell culture has the beneficial effects that the parallel communication device is arranged, so that nutrients are provided for different incubators by the same nutrition box, and meanwhile, wastes generated by the different incubators can be collected and treated by the same collection box, so that the operation steps during cell culture are reduced, and the operation efficiency is improved. And the use efficiency of the device is improved.

The invention belongs to the technical field of cell culture, and particularly relates to an umbilical cord blood NK cell culture dish and a use method thereof. The culture dish is reasonable in design, the bone marrow microenvironment is simulated through the three-dimensional micro-scaffold, and the adhesion and proliferation efficiency of cord blood NK precursor cells is remarkably improved by combining biocompatible nanofibers (PLGA) and extracellular matrix proteins (fibronectin and heparin sulfate), so that gt; the amplification multiple is 1 * 10 < 4 >. The dynamic microfluidic gradient channel continuously provides cell factors (such as IL-15 and IL-12) and nutrition, maintains stable glucose concentration (gt, 3mM) and low lactic acid level (lt, 15mM), and prevents metabolic waste from inhibiting amplification. According to the invention, an anti-CD16 antibody and an NKG2D ligand (ULBP2) are fixed on the surface, ADCC effect and tumor targeted killing ability of NK cells are enhanced through a costimulatory signal (CD137L), and cytotoxicity (K562 killing rate) gt is enhanced; 80%.

The present invention refers to a novel and efficient method for large-scale selective generation of yδ T cells, preferably human Vδ1+yδ T cells, optimal for clinical application in adoptive immunotherapy of cancer. In this sense, considering that both human cord blood HPCs, currently elected as source of stem cells in the clinic, and human early thymic progenitors can efficiently generate de novo human yδ T cells in response to Notch signalling, and most efficiently in response to the Notch ligand Jag2, the method thus comprises inducing the differentiation of cord blood CD34+ hematopoietic progenitor cells (HPCs) and / or human CD34+ early thymic progenitors, by activating them with Jag2 Notch ligands.

Cord blood or peripheral blood NK cells are prepared from whole blood mononuclear cells without the need to isolate CD34+ hematopoietic stem cells or NK cells, and without the need for a feeder layer. Advantageously, the methods presented herein use an enrichment process that uses antiCD16 agonist antibodies, antiCD3 antibodies, and N-803. Moreover, contemplated processes are suitable for adaptation into a fully automated production process (GMP in a box).

The application discloses a kind of umbilical cord blood stem cell frozen storage, belong to stem cell preservation technical field, including stem cell preservation bag;It further includes library body and storage box;Library body is provided with moving frame in, moving frame is provided with push box in;Moving frame both sides are distributed with liquid nitrogen preservation box;Liquid nitrogen preservation box back is connected liquid nitrogen storage tank by nitrogen supplementing pipe;Library body front is provided with placing cavity;Liquid nitrogen preservation box upper end is provided with the box cover that can be lifted and opened, and the tray is installed in box cover bottom;Push box front and both sides are open;The inner chamber top of push box is provided with the push rod that can be lifted and lowered and transverse movement;Push rod both ends are provided with the clamping rod for clamping storage box;Push box back is provided with push plate.The application it realizes the full-automatic quick storage and take out of umbilical cord blood stem cell, uses single small liquid nitrogen preservation box to preserve to each umbilical cord blood stem cell frozen bag, improves the preservation quality, realizes the quick identification and accurate storage management of umbilical cord blood stem cell.

The present disclosure provides methods of treating Autism Spectrum Disorder. More particularly, the present disclosure relates to methods of using cord blood tissue-derived mesenchymal stromal cells (hCT-MSCs) to treat Autism Spectrum Disorder. The methods involve treating a patient having or suspected of having an Autism Spectrum Disorder by administering a therapeutically effective amount of hCT-MSCs.

The invention relates to the technical field of biomedical processing, and particularly provides a cryopreservation method of cord blood mononuclear cells, which comprises six steps of whole blood separation, plasma inactivation, CBMC cell separation, cryopreservation liquid preparation, cell cryopreservation and detection after cryopreservation recovery. The CBMC cell separation comprises three sub-steps; performing cell cryopreservation, namely averagely dividing the separated CBMC into a plurality of parts, filling the CBMC into a cryopreservation tube according to a certain density, putting the cryopreservation tube into a programmed cooling instrument, and performing cryopreservation according to a plurality of programs; and detecting after cryopreservation and resuscitation, wherein the detection comprises three sub-steps of cell viability detection, cell recovery rate detection and cell function detection. The problems that in the cryopreservation process of a traditional method, cell viability is reduced, the number of cells is greatly reduced, cell adhesion and caking are caused, cell functions are abnormal, cell phenotypes are changed after recovery, functional activity is damaged and the like are solved, the utilization rate of the CBMC is increased, and the technical scheme is obviously superior to the traditional cell cryopreservation method; the viability, the recovery rate and the function of the recovered cells are obviously improved.

The present invention discloses a preparation method of regulatory T cell vesicles, a composite hydrogel and its application, wherein the regulatory T cell vesicle composite hydrogel comprises regulatory T cell vesicles and hydrogel, wherein the mass volume ratio of the regulatory T cell vesicles to the hydrogel is 0.5-5 g / L, and the preparation method of the regulatory T cell vesicles comprises: extracting regulatory T cells from umbilical cord blood, amplifying the extracted regulatory T cells, and obtaining amplified umbilical cord blood regulatory culture fluid; taking the supernatant of the amplified umbilical cord blood regulatory culture fluid, performing at least one centrifugation, and collecting the supernatant after centrifugation; taking the obtained supernatant, performing at least one centrifugation again, collecting the precipitate, and obtaining regulatory T cell vesicles. The regulatory T cell vesicle composite hydrogel provided by the present invention can significantly promote wound healing, and has a good therapeutic effect on the treatment of diabetic wound healing.

The invention relates to the technical field of biomedical detection, and discloses an umbilical cord blood unfreezing reference specimen cell counting and flow cytometry dilution method which comprises the following steps: S1, preparing an unfreezing solution which is composed of HES, AB plasma and PBS, and placing the unfreezing solution at room temperature for later use; s2, taking the unfrozen umbilical cord blood unfreezing reference specimen, adding an unfreezing solution into the umbilical cord blood, firstly gently and uniformly mixing, then standing at room temperature, then continuing to add the unfreezing solution, gently and uniformly mixing again, then standing at room temperature, and stabilizing; s3, taking the diluted umbilical cord blood, and carrying out cell counting by adopting a counting instrument; and S4, taking the diluted umbilical cord blood again, and dyeing. The unfreezing solution composed of HES, AB plasma and PBS synergistically regulates osmotic pressure, provides cell nutrition, stabilizes the pH value, reduces the damage of the cryoprotectant to cord blood cells, maintains the cell activity, and improves the problem of result deviation caused by direct detection of cell damage in the prior art.

The invention discloses a method for extracting and separating cord blood and placenta stem cells of sika deer, and belongs to the technical field of biomedicine. The problems that an existing stem cell extraction and separation method is low in efficiency, poor in cell activity, low in purity and large in pollution risk are solved. The method comprises the following steps: collecting cord blood and placenta after delivery of sika deer; diluting the cord blood, performing density gradient centrifugation, collecting the albuginea layer enriched with the stem cells, adding an erythrocyte lysate to remove residual erythrocytes, and centrifuging and collecting the stem cells; the method comprises the following steps: cutting placenta tissues into pieces, putting the placenta tissues into trypsin-EDTA digestive juice containing collagenase, carrying out ultrasonic-assisted digestion, and centrifuging to obtain stem cells enriched at the bottom of a centrifugal tube; and finally, resuspending the collected stem cells in a culture medium containing fetal calf serum and growth factors, adjusting the cell concentration, and inoculating into a cell culture bottle for culture. According to the method, the extraction efficiency and quality of the sika deer cord blood and placenta stem cells can be remarkably improved, and the activity and safety of the cells are ensured.

The utility model relates to a cord blood hematopoietic stem cell collection, preparation and cryopreservation integrated quadruple bag which comprises a blood collection bag, a preparation bag, a plasma bag and a cryopreservation bag, and the blood collection bag is connected with the preparation bag through a first catheter and a first three-way pipe; a first flow stopping clip is arranged on the second catheter connected between the preparation bag and the first three-way pipe; the first three-way pipe is respectively connected with the plasma bag and the cryopreservation bag through a second conduit and a second three-way pipe; a second flow stopping clip is arranged on the second catheter; a third flow stopping clip is arranged on the fourth catheter connected between the plasma bag and the second three-way pipe; and a fourth flow stopping clip is arranged on the fifth catheter connected between the second three-way pipe and the cryopreservation bag. The quadruple bag is more convenient to extract cells, the cost is reduced, the consumed time is less, the recovery rate of nucleated cells is high, and the separation effect is better.

The invention relates to the technical field of stem cell separation, and provides an umbilical cord blood hematopoietic stem cell extraction and separation device which comprises an extraction device body and a top plate, the top plate is installed at the top of the extraction device body, a pressing device is installed in the middle of the bottom of the top plate, and an umbilical cord placing plate is installed on the upper portion of the inner wall of the extraction device body. The middle of the umbilical cord placing plate penetrates through and is fixedly connected with a crushing net, the crushing net is matched with a pressing device, the upper portion and the lower portion of the middle of the inner wall of the extraction device body are each fixedly connected with two stem cell interception plates, and the middles of the two stem cell interception plates are each fixedly connected with a stem cell extraction plate. By means of the technical scheme, the problems that in the prior art, separated stem cells need to be taken out after stem cell separation is completed, and the operation that the stem cells on the filter screen need to be taken out manually in cooperation with a tool is tedious are solved.

The present disclosure provides, among other things, a method for treating systemic lupus erythematosus (SLE) or lupus nephritis by administering a therapeutically effective dose of cord blood-derived natural killer cells expressing CD19 targeting chimeric antigen receptor to a subject in need thereof. The present disclosure provides about 800 million anti- CD19 CAR-NK cells administered following a single lymphodepletion cycle for treating SLE or lupus nephritis, including relapsing or refractory SLE or lupus nephritis.

The utility model relates to the technical field of biological product instruments, and discloses a cord blood cooling box which comprises a box body, the box body comprises a box body, an outer supporting plate and an inner supporting plate, the outer supporting plate is fixed on the outer wall of the top of the box body, and the inner supporting plate is fixed on the inner wall of the top of the box body. The storage structure is arranged, the iron box containing the cord blood cryopreservation bag is placed in the inner container through the containing groove, the iron box can drive the clamping block to move to one side of the clamping pin through the supporting plate and the limiting rod by pressing the iron box, the clamping pin and the limiting rod are mutually clamped through the clamping block, the iron box is pressed again, and then the cord blood cryopreservation bag is stored. The limiting rod moves the movable block to one side of the clamping pin through the limiting block, so that the movable block and the clamping block are attached to each other, at the moment, under the elastic action of the reset spring, the limiting rod pushes away the clamping pin through the movable block, so that the clamping block and the clamping pin are separated from each other, and the functions that the device is easy to take and place and convenient to check are achieved; therefore, the applicability of the cord blood cooling box in use is improved.

Disclosed is a method for producing a stem cell with enhanced efficacy, a stem cell produced thereby, and a method for treating a disease using the same.According to the present invention, sizes of stem cells may be reduced and proliferation ability, differentiation potency, migration ability, and angiogenic potential of stem cells may be significantly enhanced by applying a culturing method provided herein. Thus the present invention may be usefully applied to development of therapeutic agents using stem cells.

Provided herein are cells or populations of cells comprising a polynucleotide encoding a cleavage resistant CD16 polypeptide. Also provided herein are methods of suppressing the proliferation of tumor cells such as HER2+ and methods of treating cancers, such as HER2+ in a subject with populations of placental-derived natural killer cells or placental-derived T cells comprising a cleavage resistant CD16. The natural killer cells, such as CYNK cells, can be placental CD34+ cell-derived natural killer (NK) cells. The placental-derived T cells can be isolated from cord blood or from placental perfusate.

A method for in vitro expansion of cryopreserved cord blood-derived regulatory T cells (Tregs) with a high recovery rate is provided, including the following steps: recovering the cryopreserved cord blood-derived Tregs after first expansion, and resuspending the cells with a serum-free medium; and adding a resulting suspension to an expansion culture medium, and conducting a second expansion culture, where a primary culture is conducted for 1 d to 2 d, then a subculture is conducted once every 1 d to 3 d, and a total culture time is 13 d or more. In the expansion culture medium, interleukin-2 (IL-2) is further added. The method can achieve the second recovery and expansion of cryopreserved Tregs produced after the first expansion. Tregs produced after the second recovery and expansion can have a viability of 90% or more, and can be further expanded (such as third expansion and fourth expansion).

The present invention relates to a cord blood concentrated cell preparation and its use in treating premature ovarian failure. In one aspect, it relates to a cell composition made from umbilical cord blood concentrated cells, comprising concentrated cells, granulocyte macrophage stimulating factor, and an optional excipient. The ratio of the concentrated cells to the granulocyte macrophage stimulating factor is such that the concentrated cells are CD45+ / - / -. + The cell count is 5x10^6 cells: 10-15 ng of granulocyte macrophage stimulating factor; the excipient is physiological saline or 5% glucose solution; the concentration of granulocyte macrophage stimulating factor in the composition is 10-15 ng / ml. The present invention also relates to a method for preparing the composition and its pharmaceutical use. The cell preparation of the present invention exhibits excellent efficacy.

An optimized method for expansion and large-scale production of regulatory T cells (Tregs) includes the following steps: preparing a cord blood-derived Treg-containing suspension; transferring the cord blood-derived Treg-containing suspension into a sterile tube matching with a magnetic pole, and magnetically sorting CD4+CD25+CD127− Tregs out; adding an expansion culture medium to Tregs carrying magnetic beads, conducting a primary culture for 1 d to 2 d, and conducting a subculture once every 1 d to 3 d, where a total culture time is 40 d to 50 d. Through one-step sorting, the method achieves very prominent cell expansion effects (shortened time and high cell viability), and increases an effective expansion time to 40 d to 50 d from 18 d. In addition, an expansion effect will not be gradually deteriorated. Thus, the method greatly increases the expansion generation number and the quantity of Tregs, and can meet the needs of clinical patients.

The present invention relates to a novel and efficient method for the large-scale selective generation of γδ T cells, preferably human V51+ γδ T cells, optimal for clinical application in adoptive immunotherapy against cancer. In this regard, taking into account that both human cord blood HPCs and human early thymic progenitor cells, the current source of stem cells of choice in the clinic, can efficiently generate de novo human γδ T cells in response to Notch signaling, most efficiently in response to the Notch ligand Jag2, the method comprises inducing the differentiation of cord blood CD34+ hematopoietic progenitor cells (HPCs) and / or human CD34+ early thymic progenitor cells by activating these progenitors with the Jag2 Notch ligand.

The invention relates to a method where / in which high number and high-activity exosomes are isolated by activating animal-derived cord blood or fetal animal blood or animal milk or other animal-derived fluids with the physical, chemical or biological methods and then the isolated and activated exosomes are hybridized with cationic liposomes to obtain a hybrid molecule with high activity, wherein the method is characterized by comprising the steps of transferring the animal cord blood into a tube / blood bag containing 1-3% Anticoagulant, gently shaking the transferred blood so as to be turned upside-down at a 90-degree angle, after completing the shaking process, transferring the blood sample into a large cylindrical chamber with a Luer Lock tip, connecting the cylindrical chamber filled with the blood to another air-tight chamber having 2 Luer Lock inlets and containing the glass grade beads (medical grade glass beads) by means of the Luer Lock tips, connecting an empty cylindrical chamber to the other end of the chamber having two Luer Lock inlets, emulsifying the blood molecules by pushing from one side to another so as to be from the cylindrical chamber filled with the blood connected to one end of the chamber containing the glass beads to the empty cylindrical chamber at the other end thereof, and then vice versa, at least 1 time per second for at least 20 repetitions, centrifuging the plasma of the blood activated by passing through the glass beads for 2-6 min at a speed of 2000-3000 G / min for obtaining two phases, separating the plasma fragment consisting of large and small proteins and exosomes as a result of the centrifugation process and isolating the exosomes in said plasma fragment by using a polymer-based precipitation method.